Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 5:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,707 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Central Nervous System Anomalies Clear all
Completed No phase listed Observational Results available

Chronic Liver Disease in Urea Cycle Disorders

NCT03721367
View directory record Official record
Conditions
Urea Cycle Disorder
Interventions
Diagnostic Ultrasound
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
5 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 10, 2026, 5:54 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

NCT01727700
View directory record Official record
Conditions
Tourette's Disorder, Tic Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
7 Years to 17 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
55
States / cities
Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2015 · Synced Oct 10, 2026, 5:54 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders

NCT01459302
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, PLS, Motor Neuron Disease, Lou Gehrigs Disease, Familial Disease, Amyotrophic Lateral Sclerosis, Sporadic, Muscular Dystrophy, Miyoshi Myopathy, Amyotrophic Lateral Sclerosis With Dementia
Interventions
Not listed
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 10, 2026, 5:54 PM EDT
Recruiting Not applicable Interventional

PHIL® Embolic System Pediatric IDE

NCT03731000
View directory record Official record
Conditions
Arterio-venous Fistula, Intracranial Arteriovenous Malformations
Interventions
PHIL® device
Device
Lead sponsor
Alejandro Berenstein
Other
Eligibility
Up to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 10, 2026, 5:54 PM EDT
Recruiting Phase 3 Interventional

BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome.

NCT07605429
View directory record Official record
Conditions
Angelman Syndrome
Interventions
rugonersen, Sham procedure
Drug · Procedure
Lead sponsor
OHB Pediatrics Ltd.
Industry
Eligibility
1 Year to 50 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
San Diego, California • Chicago, Illinois • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 10, 2026, 5:54 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria

NCT05972629
View directory record Official record
Conditions
Phenylketonuria
Interventions
SAR444836
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 10, 2026, 5:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

PCORI Urea Cycle Disorder Study

NCT02740153
View directory record Official record
Conditions
Urea Cycle Disorders
Interventions
No Intervention Given
Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
Up to 18 Years
Enrollment
187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 10, 2026, 5:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Movement Enhancing Device for Children

NCT01959581
View directory record Official record
Conditions
Upper Extremity Dysfunction
Interventions
Movement Enhancing Device
Device
Lead sponsor
University of Delaware
Other
Eligibility
1 Month to 6 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
Newark, Delaware • Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 10, 2026, 5:54 PM EDT
Not yet recruiting No phase listed Observational

Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM)

NCT07623837
View directory record Official record
Conditions
Ocular Motility Disorders, Strabismus, Extraocular Muscle Dysfunction, Thyroid Eye Disease
Interventions
Glandy EOM (AI-based quantitative eye movement analysis software)
Device
Lead sponsor
THYROSCOPE INC.
Industry
Eligibility
22 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 10, 2026, 5:54 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis

NCT04713475
View directory record Official record
Conditions
GM1 Gangliosidosis, GM1 Gangliosidosis, Type I, GM1 Gangliosidosis, Type 2, Beta-Galactosidase-1 (GLB1) Deficiency
Interventions
PBGM01
Biological
Lead sponsor
Gemma Biotherapeutics
Industry
Eligibility
1 Month to 24 Months
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Oakland, California • Minneapolis, Minnesota • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 10, 2026, 5:54 PM EDT
Completed Not applicable Interventional

Behavioral Therapy for Tourette Syndrome

NCT03019731
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Therapist-directed Behavioral Therapy, Home-based DVD Therapy
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
7 Years to 13 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 10, 2026, 5:54 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)

NCT06948019
View directory record Official record
Conditions
HSP, Hereditary Spastic Paraplegia, Hereditary Spastic Paraparesis, Hereditary Spastic Paraplegia Type 50, Hereditary Spastic Paraplegia Type 47, Hereditary Spastic Paraplegia Type 51, Hereditary Spastic Paraplegia Type 52, SPG47, AP4B1, Neurogenetic Disorders, Neurodevelopmental Conditions, Movement Disorders, Gene Therapy
Interventions
BFB-101 (AAV9-CBh-AP4B1)
Biological
Lead sponsor
BlackfinBio Ltd
Industry
Eligibility
12 Months to 60 Months
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Oct 10, 2026, 5:54 PM EDT
Recruiting Phase 2 Interventional

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

NCT06463028
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Sapanisertib, Serabelisib, Paclitaxel
Drug
Lead sponsor
Faeth Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
18
States / cities
La Jolla, California • San Francisco, California • Miami Beach, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 10, 2026, 5:54 PM EDT
Completed Phase 1 Interventional

Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors

NCT00019630
View directory record Official record
Conditions
Childhood Soft Tissue Sarcoma, Childhood Liver Cancer, Bone Cancer, Brain Tumor, Kidney Tumor
Interventions
doxorubicin HCl liposome
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Timeline
Started 1999
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 10, 2026, 5:54 PM EDT
Recruiting No phase listed Observational

Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)

NCT06805695
View directory record Official record
Conditions
Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Urea Cycle Disorders, Inborn
Interventions
No Intervention
Other
Lead sponsor
iECURE, Inc.
Industry
Eligibility
7 Months to 15 Months
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2041
U.S. locations
2
States / cities
Aurora, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 10, 2026, 5:54 PM EDT
Completed Phase 2 Interventional

Thalamic Deep Brain Stimulation for Tourette Syndrome

NCT00311909
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Thalamic deep brain stimulation
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 10, 2026, 5:54 PM EDT
Completed Not applicable Interventional Results available

Median Nerve Stimulation Pilot

NCT04731714
View directory record Official record
Conditions
Tourette Syndrome, Tic Disorders, Tic Disorder, Chronic Motor or Vocal
Interventions
Rhythmic median nerve stimulation, Arrhythmic median nerve stimulation
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
15 Years to 64 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 10, 2026, 5:54 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

NCT06270316
View directory record Official record
Conditions
Fabry Disease
Interventions
AMT-191
Drug
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 10, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)

NCT04098068
View directory record Official record
Conditions
High Tumor Mutation Burden, High TMB (Tumor Mutation Burden), MSS (Microsatellite Stable)
Interventions
MK-3475
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 10, 2026, 5:54 PM EDT
Recruiting Not applicable Interventional

Investigating Changes in Premonitory Urges During Habit Reversal Training for Tics

NCT06825520
View directory record Official record
Conditions
Tics, Tourette Disorder, Tourette Syndrome in Children, Tourette Syndrome in Adolescence
Interventions
Habit Reversal Training
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
8 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 10, 2026, 5:54 PM EDT
Not listed Not applicable Interventional

A Clinical Study to Evaluate the Safety and Efficacy of T92 in Pediatric Patients With Tourette Syndrome

NCT05188274
View directory record Official record
Conditions
Tourette Syndrome in Children, Tourette Syndrome in Adolescence
Interventions
T92, Placebo
Dietary Supplement
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 10, 2026, 5:54 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk

NCT03246243
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy, Hypoglycemia, Neonatal Abstinence Syndrome
Interventions
nfant feeding solution
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 6 Months
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 10, 2026, 5:54 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers Results available

Study to Test Sensitivity and Specificity of Passive Wave Pressure Device in Determining Ischemic Stroke

NCT01643525
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Nautilus NeuroWaveTM System
Device
Lead sponsor
Jan Medical, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Baltimore, Maryland • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Oct 10, 2026, 5:54 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers

NCT00952185
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm, Viral Infection
Interventions
cytology specimen collection procedure, fluorescent antibody technique, assessment of therapy complications
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 10, 2026, 5:54 PM EDT